{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Reyburn R"],"pubmed_abstract":["<h4>Background</h4>A systematic review in 2019 found reductions in antimicrobial resistance (AMR) of pneumococcal vaccine serotypes following pneumococcal conjugate vaccine (PCV) introduction. However, few low- or middle-income countries were included as not many had introduced higher valent PCVs (PCV10 or PCV13). The aim of our review is to describe AMR rates in these samples following the introduction of PCV10 or PCV13.<h4>Methods</h4>We conducted a systematic literature review of published papers that compared AMR for invasive pneumococcal disease (IPD), otitis media (OM) and nasopharyngeal carriage (NPC) samples following introduction of PCV10 or PCV13 to the pre-PCV period. Included studies published from July 2017 to August 2020 had a post-licensure observational study design and rep"],"journal":["Journal of global health"],"pagination":["05001"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9936452"],"repository":["biostudies-literature"],"pubmed_title":["The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: A systematic literature review."],"pmcid":["PMC9936452"],"pubmed_authors":["von Mollendorf C","Mulholland K","Graham H","Were W","Maher J","Chua P","Kevat P","Quach A","Simon J","Walker P","Russell F","ARI Review group","Neal E","Wilkes C","Reyburn R","Nisar YB","Duke T","Kazi S","Nguyen C","Gwee A","Graham S","Gray A","Hume-Nixon M","Ryan K"],"additional_accession":[]},"is_claimable":false,"name":"The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: A systematic literature review.","description":"<h4>Background</h4>A systematic review in 2019 found reductions in antimicrobial resistance (AMR) of pneumococcal vaccine serotypes following pneumococcal conjugate vaccine (PCV) introduction. However, few low- or middle-income countries were included as not many had introduced higher valent PCVs (PCV10 or PCV13). The aim of our review is to describe AMR rates in these samples following the introduction of PCV10 or PCV13.<h4>Methods</h4>We conducted a systematic literature review of published papers that compared AMR for invasive pneumococcal disease (IPD), otitis media (OM) and nasopharyngeal carriage (NPC) samples following introduction of PCV10 or PCV13 to the pre-PCV period. Included studies published from July 2017 to August 2020 had a post-licensure observational study design and rep","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T23:13:05.442Z","creation":"2025-04-04T23:13:05.442Z"},"accession":"S-EPMC9936452","cross_references":{"pubmed":["36799235"],"doi":["10.7189/jogh.13.05001"]}}